Serostim (Somatropin) Patent Expiration, LOE Window & CMS Spending
Serostim (Somatropin) by Emd Serono: Biologic BLA (Purple Book Regime), 0 AB generics, $117.4M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Emd Serono |
| FDA Application & Pathway | B020604 (BLA) |
| Exclusivity / Cliff Horizon | Biologic BLA (Purple Book Regime) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $117.4M |
| 2024 Medicare Part D Spend | $109.5M |
| 2024 Medicaid Spend | $7.8M |
| Reported Wholesale Price Change (CA SB 17) | 6 WAC filings (max 19.8% 2-yr change) |